1622093-56-4

Basic information

• Product Name: N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-2-morpholinoacetamide
• Synonyms: N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-2-morpholinoacetamide
• CAS NO: 1622093-56-4
• Molecular Weight: 609.687
• Mol File: 1622093-56-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-2-morpholinoacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-2-morpholinoacetamide(1622093-56-4)
• EPA Substance Registry System: N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-2-morpholinoacetamide(1622093-56-4)

Safety Data

• Hazardous Substances Data: 1622093-56-4(Hazardous Substances Data)

Upstream product

• 921201-86-7 N-(4-azido-phenyl)-2-(morpholin-4-yl)-acetamide 
• 1622093-52-0 2-(4-(prop-2-yn-1-yloxy)phenyl)-1H-phenanthro[9,10-d]imidazole 
• 105076-76-4 N-(4-amino-phenyl)-2-(morpholin-4-yl)-acetamide 
• 262368-13-8 2-morpholin-4-yl-N-(4-nitro-phenyl)-acetamide 
• 17329-87-2 2-chloro-N-(4-nitro-phenyl)-acetamide 
• 100-01-6 4-nitro-aniline 

Relevant articles and documents

Synthesis and characterization of 1H-phenanthro[9,10-d]imidazole derivatives as multifunctional agents for treatment of Alzheimer's disease

Background Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder that is characterized by dementia, cognitive impairment, and memory loss. Diverse factors are related to the development of AD, such as increased level of β-amyloid (Aβ), acetylcholine, metal ion deregulation, hyperphosphorylated tau protein, and oxidative stress. Methods The following methods were used: organic syntheses of 1H-phenanthro[9,10-d] imidazole derivatives, inhibition of self-mediated and metal-induced Aβ1-42 aggregation, inhibition studies for acetylcholinesterase and butyrylcholinesterase, anti-oxidation activity studies, CD, MTT assay, transmission electron microscopy, dot plot assay, gel electrophoresis, Western blot, and molecular docking studies. Results We synthesized and characterized a new type of 1H-phenanthro[9,10-d]imidazole derivatives as multifunctional agents for AD treatment. Our results showed that most of these derivatives exhibited strong Aβ aggregation inhibitory activity. Compound 9g had 74% Aβ1-42 aggregation inhibitory effect at 10 μM concentration with its IC50 value of 6.5 μM for self-induced Aβ1-42 aggregation. This compound also showed good inhibition of metal-mediated (Cu2 + and Fe2 +) and acetylcholinesterase-induced Aβ1-42 aggregation, as indicated by using thioflavin T assay, transmission electron microscopy, gel electrophoresis, and Western blot. Besides, compound 9g exhibited cholinesterase inhibitory activity, with its IC50 values of 0.86 μM and 0.51 μM for acetylcholinesterase and butyrylcholinesterase, respectively. In addition, compound 9g showed good anti-oxidation effect with oxygen radical absorbance capacity (ORAC) value of 2.29. Conclusions Compound 9g was found to be a potent multi-target-directed agent for Alzheimer's disease. General significance Compound 9g could become a lead compound for further development as a multi-target-directed agent for AD treatment.